HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

Chongqing Zhifei Biological Products- Promising Future After Successful Renewal of Contract with MSD

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

Hygeia Healthcare Group (6078 HK) - Good Business Model with Large Market Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Bloomage Biotechnology  Lt / Equity Bottom-Up

<p>In January, 2021, National Health Commission has approved hyaluronic acid as a new food ingredient, which could be used in common foods. This marks the further opening of China's hyaluronic acid food market and the new development milestone of China's hyaluronic acid industry. <a href="https://www.smartkarma.com/entities/bloomage-biotechnology-corporation-a" target="_blank" data-smartkarma-citation="entities:30390:1" rel="noopener">Bloomage Biotechnology Corporation-A (688363 CH)</a> is the global leader in the raw materials of hyaluronic acid, and it has broken through the whole industrial chain from the upstream hyaluronic acid raw materials to the downstream of the medical beauty, functional skin care and functional food. Besides, because of the new regulation, the Company's food grade raw materials business and functional food products are expected to shift from export to domestic sales, further opening the Company's growth space. It is expected that Bloomage’s future growth would be promising.</p>

In January, 2021, National Health Commission has approved hyaluronic acid as a new food ingredient, which could be used in common foods. This marks the further opening of China's hyaluronic acid food market and the new development milestone of China's hyaluronic acid industry. Bloomage Biotechnology Corporation-A (688363 CH) is the global leader in the raw materials of hyaluronic acid, and it has broken through the whole industrial chain from the upstream hyaluronic acid raw materials to the downstream of the medical beauty, functional skin care and functional food. Besides, because of the new regulation, the Company's food grade raw materials business and functional food products are expected to shift from export to domestic sales, further opening the Company's growth space. It is expected that Bloomage’s future growth would be promising.

Shanghai Haohai Biological Tec (688366 CH)

Bloomage Biotechnology (688363.CH) - Accelerated Growth with the Approval of New Regulation